ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2151

Fractalkine (CX3CL1) Is Expressed By Arterial Endothelium and Vascular Smooth Muscle Cells (VSMC) in GCA

Marc Corbera-Bellalta1, Ester Planas-Rigol2, Nekane Terrades-Garcia1, Marco Antonio Alba1, Georgina Espígol-Frigolé2, Sergio Prieto-González2, Jose Hernández-Rodríguez1 and Maria C. Cid3, 1Vasculitis Research Unit. Department of Autoimmune Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 2Department of Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain, 3Autoimmune and Systemic Diseases, Hospital Clínic. University of Barcelona. IDIBAPS, Barcelona, Spain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: chemokines, cytokines, giant cell arteritis, inflammation and vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 15, 2016

Title: Cytokines, Mediators, Cell-Cell Adhesion, Cell Trafficking and Angiogenesis - Poster II

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: The development of giant-cell arteritis (GCA) lesions requires amplification cascades resulting in continuous recruitment of lymphocytes and monocytes. Interferon-gamma (IFNg)- induced or up-regulated chemokines CCL-2, CXCL9, CXCL10, and CXCL11 play an important role in inflammatory cell recruitment, a process in which not only endothelial cells but also vascular smooth muscle cells (VSMC) seem to be involved (Corbera-Bellalta M et al Ann Rheum Dis 2016). CX3CL1, also known as fractalkine, and along with its unique receptor CX3CR1, are the only members of CX3C chemokine/ chemokine receptor family. CX3CL1 has two isoforms mediating different functions. The transmembrane protein form regulates cell adhesion, while the soluble one (generated by proteolytic cleavage) has chemotactic function. Soluble fractalkine is elevated in serum from patients with small-vessel vasculitis. However, expression of fractalkine and its receptor have not been explored in GCA. To explore CXCL1/CXCR1 expression in GCA lesions and in temporal artery- derived VSMC. 

Methods: RNA was extracted from fresh temporal arteries of 12 GCA patients and 8 healthy controls using chloroform-isopropanol classic method. CX3CL1 mRNA expression was assessed by quantitative real-time PCR (Applied Biosystems). Fresh arteries from 1 GCA patient and 1 control were subjected to immunofluorescence using specific antibodies (Cell Signaling). VSMC obtained from cultured temporal arteries were treated with IFNg and/or TNFa for 3 days, and CX3CL1 expression by VSMC was detected by realtime PCR.

Results: CX3CL1 mRNA expression was constitutively expressed by control arteries and downregulated in GCA lesions compared with controls, probably due to VSMCs loss in the media of inflamed arteries. Consistently, immunofluorescence studies disclosed that CX3CL1 protein expression was intensively expressed by the endothelium of the GCA-involved artery and by VSMC remaining in the media. CX3CR1 was expressed by infiltrating leukocytes in GCA. As with other chemokines, CX3CL1 expression was significantly up regulated in VSMC cultured in the presence of inflammatory mediators (IFNg and TNFa). VSMC did not express CX3CR1.

Conclusion: Fractalkine and its receptor are expressed in GCA lesions. VSMCs react to the presence of inflammatory cytokines by expressing CX3CL1, highlighting a possible role of this chemokine not only in leukocyte recruitment by endothelial cells but also in leukocyte progression through the VSMC in the medial layer. Functional chemotaxis studies are ongoing to confirm this point. Supported by SAF 2014/57708-R and PIE13/00033


Disclosure: M. Corbera-Bellalta, None; E. Planas-Rigol, None; N. Terrades-Garcia, None; M. A. Alba, None; G. Espígol-Frigolé, None; S. Prieto-González, None; J. Hernández-Rodríguez, None; M. C. Cid, None.

To cite this abstract in AMA style:

Corbera-Bellalta M, Planas-Rigol E, Terrades-Garcia N, Alba MA, Espígol-Frigolé G, Prieto-González S, Hernández-Rodríguez J, Cid MC. Fractalkine (CX3CL1) Is Expressed By Arterial Endothelium and Vascular Smooth Muscle Cells (VSMC) in GCA [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/fractalkine-cx3cl1-is-expressed-by-arterial-endothelium-and-vascular-smooth-muscle-cells-vsmc-in-gca/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fractalkine-cx3cl1-is-expressed-by-arterial-endothelium-and-vascular-smooth-muscle-cells-vsmc-in-gca/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology